A5047054576- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Computational Drug Discovery Methods
- Biochemical and Molecular Research
- COVID-19 diagnosis using AI
- Infectious Diseases and Mycology
Research Center Borstel - Leibniz Lung Center
2020-2024
For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC) distributions of wild-type isolates have not been systematically evaluated despite their importance for establishing antimicrobial susceptibility testing (AST) breakpoints. We gathered MIC drugs used against the Mycobacterium avium complex (MAC) and abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFFs) tentative ECOFFs (TECOFFs)...
The Roche cobas MTB and MTB-RIF/INH assays allow for detection of Mycobacterium tuberculosis complex (MTBC) nucleic acid rifampicin (RIF) isoniazid (INH) resistance-associated mutations in an automated, high-throughput workflow. In this study, we evaluated the performance these assays, employing samples from settings low high (TB) burdens. A total 325 frozen, leftover respiratory collected treatment-naive patients with presumptive TB Germany (n = 280) RIF-resistant Sierra Leone 45) were used...
This study evaluated the performance of cobas MTB and MTB-RIF/INH for diagnosis tuberculosis detection rifampicin (RIF) isoniazid (INH) resistance. Adults presenting with pulmonary symptoms were recruited in South Africa, Moldova, India. Performance was assessed against culture, whereas using phenotypic drug susceptibility testing whole-genome sequencing as composite reference standards. Xpert MTB/RIF (Xpert) or Ultra (Ultra) used a comparator. The overall sensitivity specificity 95% (95%...